Search

Copyright of Journal of Uludag University Medical Faculty / Uludağ Üniversitesi Tıp Fakültesi Dergisi is the property of Journal of Uludag University Medical Faculty and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose: In this study, we aimed to determine the effects of autophagy inhibitor and activator on Cisplatin (Cis)-induced tissue damage. Materials and Methods: A total of 24 male Wistar albino rats were divided into 4 groups including 6 rats per group in this study. Groups are as follows; Control, Cisplatin (Cis) (8 mg/kg), Rapamycin (Rapa) (2 mg/kg), 3-methyladenine (3-MA) (15 mg/kg). Rapa and 3-MA were given intraperitoneally for 15 days. Cis was administered as a single dose on the 7th day of the experimental period. At the end of the experimental procedure, epididymis tissues were extracted. Hematoxylin and eosin staining and Heat shock protein-70 (HSP70) immunohistochemistry were applied to the sections taken after histological techniques. Results: Dispersion in the tubule basement membrane and vacuolization in the tubule was observed in the Cis group. It was also observed that some epithelial cells were more eosinophilic in the Cis group. Tissue sections of Rapa and 3-MA had a more regular appearance in terms of epithelization and tubule basement membrane. HSP70 immunoreactivity was observed in the intertubuler connective tissue of all groups. Conclusion: The epididymis was affected by agents such as Cis in terms of the protection of semen quality and potency of spermatozoa. Rapa may be more effective than 3-MA in the epididymis against Cis toxicity.

In the conventional medical understanding, the focus has been on diseases, the same treatment methods have been applied to different individuals with the same disease, but the fact that the same disease will not be the same in different people and therefore the treatment cannot be the same has emerged. For this reason, individuals are more prominent than disease, and in this context, precision medicine concept has entered our lives with the developing technological infrastructure. Although the term precision medicine is relatively new, the concept has been a part of healthcare for many years. In the treatment of immunological diseases, sensitive medicine treatment strategies basically include three different treatment approaches. Replacement of ""missing molecules", inhibition of overactive intracellular signaling and cytokine blockade. Along with the treatment approaches which have been most frequently used in immunology clinics for many years such as IVIG, PEG-ADA and IFN-y, precision medicine also includes relatively rarer treatments that have been discovered lately such as pleriksafor, sirolimus and vedolizumab. Defining new molecular pathways with today's increasing technological infrastructure will undoubtedly bring the days when the concept of precision medicine will be used more effectively in the treatment of many diseases. [ABSTRACT FROM AUTHOR]

Background: To investigate the effect of Tc99m exposure on tacrolimus, everolimus, sirolimus and cyclosporin A levels measured by blood LC / MSMS used in scintigraphic imaging techniques. Materials and Methods: HPLC solvents, reagents (I Jasem, Turkey), calibrator and control solutions for the study were employed. The Tc99m preparation was used for the interference study. Immunosuppressant measurement was performed by Shimadzu 8045 triple quadrupole mass spectrometry (MS / MS) (Shimadzu, Japan), which was integrated with Shimadzu Nexera X2 ultra high-performance liquid chromatography (UHPLC). Device data was calculated with Shimadzu Software. For sample preparation, 500 microliters (LL) of control solution was transferred to the centrifuge tube. 25 uL of internal standard was added and mixed with vortex for 5 seconds. All procedures for interference study were repeated for level1, level2 and level3 control solutions and performed by LC/MS-MS. Interference protocol was repeated by adding 50uL of distilled water to each level of control. Results: Bias was detected in the range of 6.28% to 47.21% in all sirolimus measurements. Tacrolimus levels deviated from the target value in the range of 21.81% to 44.62%. For cyclosporine A levels, bias was calculated between 9,30% - 43,16%. The least deviation was observed in Sirolimus level 3 with 6.28% and the maximum deviation was observed in sirolimus level 1. Conclusion: The Tc99m radionuclide used in scintigraphic imaging has the potential to affect immunosuppressant levels measured by LC / MS-MS devices. Health service staffs making sampling should be informed about this and physicians should consider the interference posibility in suspicious immunosuppressant concentrations. [ABSTRACT FROM AUTHOR]

The mammalian target of rapamycin (mTOR) is a highly conserved in evolution serine/threonine kinase belonging to the phosphatidylinositol kinase related protein kinases family. mTOR plays a central role in regulation of a number of cellular function inculuding especialy cell growth, metabolism and proliferation and in ensuring cellular homeostasis. Once of basic signalling pathway that has been described as important in cancer including phosphatidylinositol 3-kinase (PI3K)/AKT/kinase cascade. These pathway are frequently deteriorated in cancer, and therefore mTOR inhibition is a important antitumor target. mTOR inhibitors include rapamycin (i.e. sirolimus) and its derivatives; temsirolimus, everolimus and deforolimus (ridaforolimus). Rapamycin and analogs inhibit proliferation of cancer cells in both in vitro and in vivo. mTOR inhibitors have the important potential to provide anticancer activity in many tumor types. [ABSTRACT FROM AUTHOR]

Mammalian target of rapamycin (mTOR) plays a major role in the regulation of protein translation, cell growth, and metabolism. Three basic signalling pathways that have been described as important in cancer including the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR kinase cascade, the protein kinase C (PKC) family, and the mitogen-activated protein kinase (MAPK)/Ras signalling cascades. mTOR has been defined as a key kinase acting downstream of the activation of PI3K/AKT. These pathways are frequently deteriorated in cancer, and therefore mTOR inhibition is a important antitumor target. mTOR inhibitors include rapamycin (i.e. sirolimus) and its derivatives; temsirolimus, everolimus, ridaforolimus and deforolimus. mTOR inhibitors has the important potential to provide anticancer activity in many tumor types. [ABSTRACT FROM AUTHOR]